PDGFRB and neoplasm: Nevertheless, sorafenib was highly anti-angiogenic in our experiments, presumably due to inhibition of its other tyrosine kinase targets important for tumor angiogenesis, including Raf, c-Kit, PDGFR-β and Flt-3 [33].